Combination chemotherapy with irinotecan and cisplatin in elderly patients (≥65 years) with extensive-disease small-cell lung cancer

Lung Cancer

Volumn 61, Issue 2, 2008, Pages 220-226

  Kim, Hoon Gu ^a,b,c   Lee, Gyeong Won ^a,b,c   Kang, Jung Hun ^a,b,c   Kang, Myung Hee ^a,b,c   Hwang, In Gyu ^d   Kim, Seok Hyun ^a   Hahm, Jong Ryeal ^a,b   Jeong, Yi Yeong ^a,b,c   Kim, Ho Cheol ^a,b,c   Lee, Jong Duk ^a,b,c   Lee, Jong Seok ^e   Hwang, Young Sil ^a,b,c  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

^d Kangwon National University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Cisplatin; Elderly; Irinotecan; Small cell lung cancer

Indexed keywords

CISPLATIN; IRINOTECAN;

AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEUTROPENIA;

EID: 47649114357     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.020     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Shin H.R., Jung K.W., Won Y.J., and Park J.G. 139 KCCR-affiliated Hospitals. 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals. Cancer Res Treat 36 2 (2004) 103-114
3. Bunn P.A., and Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 95 (2003) 341-343
4. Surveillance, Epidemiology, and End Results (SEER): Cancer Statistics Review 1975-2004, National Cancer Institute. Bethesda, MD. http://www.seer.cancer.gob/csr/1975_2004/.
5. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
6. Noda K., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
7. Hong Y.S., Lee H.R., Park S., Lee S.C., Hwang I.G., Park B.B., et al. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. Br J Cancer 95 12 (2006) 1648-1652
8. Takigawa N., Kiura K., Tabata M., and Tanimoto M. Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer. J Clin Oncol 24 32 (2006) 5175 author reply 5175-6
9. Sohn J.H., Choi H.J., Chang J., Kim S.K., Lee C.G., Chung K.Y., et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small-cell lung cancer. Lung Cancer 54 3 (2006) 365-370
10. Okamoto H., Naoki K., Narita Y., Hida N., Kunikane H., and Watanabe K. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer 53 2 (2006) 197-203
11. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 13 (2006) 2038-2043
12. Lara Jr. P.N., Gandara D.R., and Natale R.B. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer 7 5 (2006) 353-356
13. Schmittel A., Fischer von Weikersthal L., Sebastian M., Martus P., Schulze K., Hortig P., et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 17 4 (2006) 663-667
14. Han J.Y., Lee D.H., Lee S.Y., Park C.G., Kim H.Y., Kim E.A., et al. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer. Med Oncol 22 3 (2005) 281-290
15. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
17. Hanna N. ASCO education book. 2006. 445-8.
18. Ardizzoni A., Favaretto A., Boni L., et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multucenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis-A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23 (2005) 569-575
19. Okamoto H., Watanabe K., Kunikane H., Yokoyama A., Kudoh S., Asakawa T., et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97 2 (2007) 162-169
20. Rossi A., Maione P., Colantuoni G., Guerriero C., Ferrara C., Del Gaizo F., et al. Treatment of small cell lung cancer in the elderly. Oncologist 10 6 (2005) 399-411
21. Thongprasert S., Soorraritchingchai S., Chewaskulyong B., Charoentum C., and Munprakan S. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer. J Med Assoc Thai 89 2 (2006) 152-159
22. Mandrekar S.J., Schild S.E., Hillman S.L., Allen K.L., Marks R.S., Mailliard J.A., et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107 4 (2006) 781-792
23. Jatoi A., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 23 36 (2005) 9113-9119
24. Harvie M.N., Howell A., Thatcher N., Baildam A., and Campbell I. Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy-a longitudinal study. Br J Cancer 92 4 (2005) 673-680
25. Perrone F., Di Maio M., Gallo C., and Gridelli C. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 22 24 (2004) 5018-5020
26. Gridelli C., De Vivo R., and Monfardini S. Management of small-cell lung cancer in the elderly. Crit Rev Oncol Hematol 41 1 (2002) 79-88
27. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 Suppl 1 (2001) 4-7
28. Jara C., Gomez-Aldaravi J.L., Tirado R., Meseguer V.A., Alonso C., and Fernandez A. Small-cell lung cancer in the elderly-is age of patient a relevant factor?. Acta Oncol 38 6 (1999) 781-786